Interpace Biosciences, Inc. (IDXG) stock
IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)
Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –
Interpace Biosciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Interpace Biosciences's ebitda for the twelve months ending Jun 30, 2026 was $4.64M, down 23.9% year over year. For fiscal 2025 it was $4.51M, down 46.4% from the year before. The highest annual figure on record is $8.41M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.51M | -46.4% |
| FY2024 | Dec 31, 2024 | $8.41M | +68.8% |
| FY2023 | Dec 31, 2023 | $4.98M | – |
| FY2022 | Dec 31, 2022 | -$1.06M | – |
| FY2021 | Dec 31, 2021 | -$962.00K | – |
| FY2020 | Dec 31, 2020 | -$20.57M | – |
| FY2019 | Dec 31, 2019 | -$21.91M | – |
| FY2018 | Dec 31, 2018 | -$8.83M | – |
| FY2017 | Dec 31, 2017 | -$2.60M | – |
| FY2016 | Dec 31, 2016 | -$1.96M | – |
| FY2015 | Dec 31, 2015 | -$35.38M | – |
| FY2014 | Dec 31, 2014 | -$15.44M | – |
| FY2013 | Dec 31, 2013 | -$12.00K | – |
| FY2012 | Dec 31, 2012 | -$23.20M | – |
| FY2011 | Dec 31, 2011 | -$1.66M | – |
| FY2010 | Dec 31, 2010 | -$5.07M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $448.00K | – |
| Q1 FY2026 | Mar 31, 2026 | $1.24M | -35.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.70M | -21.4% |
| Q3 FY2025 | Sep 30, 2025 | $1.26M | -47.4% |
| Q2 FY2025 | Jun 30, 2025 | -$367.00K | -113.6% |
| Q1 FY2025 | Mar 31, 2025 | $1.92M | +65.0% |
| Q4 FY2024 | Dec 31, 2024 | $2.16M | +38.0% |
| Q3 FY2024 | Sep 30, 2024 | $2.39M | +266.0% |
| Q2 FY2024 | Jun 30, 2024 | $2.70M | +71.5% |
| Q1 FY2024 | Mar 31, 2024 | $1.17M | -2.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.56M | +282.8% |
| Q3 FY2023 | Sep 30, 2023 | $652.00K | – |
| Q2 FY2023 | Jun 30, 2023 | $1.57M | – |
| Q1 FY2023 | Mar 31, 2023 | $1.19M | – |
| Q4 FY2022 | Dec 31, 2022 | $408.00K | – |
| Q3 FY2022 | Sep 30, 2022 | -$145.00K | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.12M | – |
| Q1 FY2022 | Mar 31, 2022 | -$196.00K | – |
| Q4 FY2021 | Dec 31, 2021 | -$328.00K | – |
| Q3 FY2021 | Sep 30, 2021 | -$418.00K | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.50M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.28M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.54M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.61M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.38M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.03M | – |
| Q4 FY2019 | Dec 31, 2019 | -$9.41M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.89M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.39M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.23M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.80M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.60M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.04M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.39M | -151.2% |
| Q4 FY2017 | Dec 31, 2017 | -$2.42M | -131.3% |
| Q3 FY2017 | Sep 30, 2017 | -$2.22M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.63M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.67M | – |
| Q4 FY2016 | Dec 31, 2016 | $7.73M | – |
| Q3 FY2016 | Sep 30, 2016 | -$5.39M | – |
See a number that looks wrong?